Cancer immunotherapy has transformed cancer treatment, yet many patients experience limited or short-lived responses due to immune evasion, tumor heterogeneity, and immune-related adverse events. While the role of MHC-I in antigen…
Review highlights emerging role of tumor MHC-II in shaping cancer immunotherapy outcomes
